Collegium Pharmaceutical Inc (COLL)
ROA
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 48 155 | 9 016 | -11 161 | -29 359 | -25 002 | -42 837 | -35 248 | 42 786 |
| Aktywa razem | w tys. USD | 1 143 310 | 1 177 580 | 1 213 910 | 1 214 300 | 1 174 130 | 1 200 940 | 1 245 570 | 1 246 140 |
| ROA | 4,21% | 0,77% | -0,92% | -2,42% | -2,13% | -3,57% | -2,83% | 3,43% |
2023/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $48 155K ÷ $1 143 310K
= 4,21%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROA
Collegium Pharmaceutical Inc
COLL
4,21%
Amphastar Pharmaceuticals Inc
AMPH
9,09%
Arcus Biosciences Inc
RCUS
-28,04%
Catalyst Pharmaceuticals Inc
CPRX
15,19%
Dynavax Technologies Corp.
DVAX
-0,64%
Innoviva Inc
INVA
14,45%
Ironwood Pharmaceuticals Inc
IRWD
-212,76%
Ligand Pharmaceuticals, Inc.
LGND
6,63%
Medifast Inc
MED
32,08%
Myriad Genetics, Inc.
MYGN
-22,97%
Xencor Inc
XNCR
-13,23%